Eli Lilly and (LLY) 10-K Summary — Year Ended Dec 31, 2024
Eli Lilly filed its annual report for the period. The company reported strong revenue growth and continued investment in manufacturing capacity.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Eli Lilly filed its annual report for the period. The company reported strong revenue growth and continued investment in manufacturing capacity.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$45B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$10.6B
Net income reported for the year.
Operating cash flow
$8.8B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $28.3B | n/a |
| Dec 31, 2022 | $28.5B | +0.8% |
| Dec 31, 2023 | $34.1B | +19.6% |
| Dec 31, 2024 | $45B | +32.0% |
Business overview
Eli Lilly is a pharmaceutical company focused on discovering, developing, and marketing medicines. The company's portfolio includes treatments for various diseases, with a particular emphasis on incretin-based therapies.
Financial performance
Revenue increased compared to the prior year, continuing a trend of growth. The company's net income improved, reflecting higher sales and operational efficiency.
Material risks
Key risks include the company's reliance on the success of new products, particularly in the incretin class. Additionally, the company faces risks related to manufacturing expansion and supply chain commitments.
Liquidity and capital
Capital expenditures increased significantly due to investments in global manufacturing facilities. The company has entered into agreements that could require substantial payments if certain purchase commitments are not met.
What to watch
Monitor the company's progress in expanding manufacturing capacity to meet demand for its incretin medicines.